05:37 PM EST, 03/05/2025 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said the US Food and Drug Administration approved a lower dosage of neffy for allergic emergencies, including anaphylaxis.

The regulator approved a 1 milligram version of the nasal spray for children 4 years and up, the company said Wednesday in a statement.

A 2 mg version of neffy, an epinephrine nasal spray, was approved in the US in 2024.

ARS shares rose 5.1% in after-hours trading.